Arterial and Venous Thrombotic Events in Urological Malignancy—A Real-World Cohort Study from a Tertiary Urology Referral Center

Background/Objectives: Cancer-associated thrombosis (CAT) increases morbidity and mortality in cancer patients. To describe CAT in urological malignancies and explore associated factors, timing, Khorana score performance and systemic inflammatory indices.

Methods

This retrospective study included 1044 patients. Oncological, cardiovascular and laboratory data from medical records were compared by CAT status. Firth penalized logistic regression was used for sparse-event analyses.

Results

Thirty-one patients (2.97%) developed CAT, including 17 arterial thrombotic events (ATE) and 14 venous thromboembolic events (VTE). Advanced stage was associated with CAT (adjusted odds ratio [aOR] per stage 1.60, 95% confidence interval [CI] 1.21–2.17; p < 0.001) in the primary and sensitivity analyses. In an exploratory analysis, cardiovascular disease was associated with ATE (odds ratio [OR] 4.58, 95% CI 1.67–15.16; Benjamini–Hochberg [BH]-adjusted q = 0.031), although the small number of ATE precluded a reliable subgroup conclusion. Median time from cancer diagnosis to CAT was 3 months. The Khorana score did not show useful VTE discrimination in the systemic chemotherapy subgroup (77 patients; four VTE; area under the receiver operating characteristic curve [AUC] 0.437, 95% CI 0.127–0.746). The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic inflammation response index (SIRI), and systemic immune-inflammation index (SII) showed no useful discrimination (AUCs 0.487–0.513) or improvement of the clinical model (all BH-adjusted q = 0.963).